Innate immune cells for immunotherapy of autoimmune and cancer disorders

Carolina Schäfer, Gabriel Ascui, Carolina H. Ribeiro, Mercedes López, Rafael Prados-Rosales, Pablo A. González, Susan M. Bueno, Claudia A. Riedel, Andrés Baena, Alexis M. Kalergis, Leandro J. Carreño

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Modulation of the immune system has been widely targeted for the treatment of several immune-related diseases, such as autoimmune disorders and cancer, due to its crucial role in these pathologies. Current available therapies focus mainly on symptomatic treatment and are often associated with undesirable secondary effects. For several years, remission of disease and subsequently recovery of immune homeostasis has been a major goal for immunotherapy. Most current immunotherapeutic strategies are aimed to inhibit or potentiate directly the adaptive immune response by modulating antibody production and B cell memory, as well as the effector potential and memory of T cells. Although these immunomodulatory approaches have shown some success in the clinic with promising therapeutic potential, they have some limitations related to their effectiveness in disease models and clinical trials, as well as elevated costs. In the recent years, a renewed interest has emerged on targeting innate immune cells for immunotherapy, due to their high plasticity and ability to exert a potent and extremely rapid response, which can influence the outcome of the adaptive immune response. In this review, we discuss the immunomodulatory potential of several innate immune cells, as well as they use for immunotherapy, especially in autoimmunity and cancer.

Original languageEnglish
Pages (from-to)315-337
Number of pages23
JournalInternational Reviews of Immunology
Volume36
Issue number6
DOIs
Publication statusPublished - 2 Nov 2017

Fingerprint

Immunotherapy
Adaptive Immunity
Neoplasms
Aptitude
Immune System Diseases
Therapeutics
Autoimmunity
Antibody Formation
Immune System
Homeostasis
B-Lymphocytes
Clinical Trials
Pathology
T-Lymphocytes
Costs and Cost Analysis

Keywords

  • autoimmunity
  • cancer
  • dendritic cells
  • Innate immunity
  • NKT cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Schäfer, C., Ascui, G., Ribeiro, C. H., López, M., Prados-Rosales, R., González, P. A., ... Carreño, L. J. (2017). Innate immune cells for immunotherapy of autoimmune and cancer disorders. International Reviews of Immunology, 36(6), 315-337. https://doi.org/10.1080/08830185.2017.1365145
Schäfer, Carolina ; Ascui, Gabriel ; Ribeiro, Carolina H. ; López, Mercedes ; Prados-Rosales, Rafael ; González, Pablo A. ; Bueno, Susan M. ; Riedel, Claudia A. ; Baena, Andrés ; Kalergis, Alexis M. ; Carreño, Leandro J. / Innate immune cells for immunotherapy of autoimmune and cancer disorders. In: International Reviews of Immunology. 2017 ; Vol. 36, No. 6. pp. 315-337.
@article{d1150053c8054c20be986bb617372f6c,
title = "Innate immune cells for immunotherapy of autoimmune and cancer disorders",
abstract = "Modulation of the immune system has been widely targeted for the treatment of several immune-related diseases, such as autoimmune disorders and cancer, due to its crucial role in these pathologies. Current available therapies focus mainly on symptomatic treatment and are often associated with undesirable secondary effects. For several years, remission of disease and subsequently recovery of immune homeostasis has been a major goal for immunotherapy. Most current immunotherapeutic strategies are aimed to inhibit or potentiate directly the adaptive immune response by modulating antibody production and B cell memory, as well as the effector potential and memory of T cells. Although these immunomodulatory approaches have shown some success in the clinic with promising therapeutic potential, they have some limitations related to their effectiveness in disease models and clinical trials, as well as elevated costs. In the recent years, a renewed interest has emerged on targeting innate immune cells for immunotherapy, due to their high plasticity and ability to exert a potent and extremely rapid response, which can influence the outcome of the adaptive immune response. In this review, we discuss the immunomodulatory potential of several innate immune cells, as well as they use for immunotherapy, especially in autoimmunity and cancer.",
keywords = "autoimmunity, cancer, dendritic cells, Innate immunity, NKT cells",
author = "Carolina Sch{\"a}fer and Gabriel Ascui and Ribeiro, {Carolina H.} and Mercedes L{\'o}pez and Rafael Prados-Rosales and Gonz{\'a}lez, {Pablo A.} and Bueno, {Susan M.} and Riedel, {Claudia A.} and Andr{\'e}s Baena and Kalergis, {Alexis M.} and Carre{\~n}o, {Leandro J.}",
year = "2017",
month = "11",
day = "2",
doi = "10.1080/08830185.2017.1365145",
language = "English",
volume = "36",
pages = "315--337",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "6",

}

Schäfer, C, Ascui, G, Ribeiro, CH, López, M, Prados-Rosales, R, González, PA, Bueno, SM, Riedel, CA, Baena, A, Kalergis, AM & Carreño, LJ 2017, 'Innate immune cells for immunotherapy of autoimmune and cancer disorders', International Reviews of Immunology, vol. 36, no. 6, pp. 315-337. https://doi.org/10.1080/08830185.2017.1365145

Innate immune cells for immunotherapy of autoimmune and cancer disorders. / Schäfer, Carolina; Ascui, Gabriel; Ribeiro, Carolina H.; López, Mercedes; Prados-Rosales, Rafael; González, Pablo A.; Bueno, Susan M.; Riedel, Claudia A.; Baena, Andrés; Kalergis, Alexis M.; Carreño, Leandro J.

In: International Reviews of Immunology, Vol. 36, No. 6, 02.11.2017, p. 315-337.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Innate immune cells for immunotherapy of autoimmune and cancer disorders

AU - Schäfer, Carolina

AU - Ascui, Gabriel

AU - Ribeiro, Carolina H.

AU - López, Mercedes

AU - Prados-Rosales, Rafael

AU - González, Pablo A.

AU - Bueno, Susan M.

AU - Riedel, Claudia A.

AU - Baena, Andrés

AU - Kalergis, Alexis M.

AU - Carreño, Leandro J.

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Modulation of the immune system has been widely targeted for the treatment of several immune-related diseases, such as autoimmune disorders and cancer, due to its crucial role in these pathologies. Current available therapies focus mainly on symptomatic treatment and are often associated with undesirable secondary effects. For several years, remission of disease and subsequently recovery of immune homeostasis has been a major goal for immunotherapy. Most current immunotherapeutic strategies are aimed to inhibit or potentiate directly the adaptive immune response by modulating antibody production and B cell memory, as well as the effector potential and memory of T cells. Although these immunomodulatory approaches have shown some success in the clinic with promising therapeutic potential, they have some limitations related to their effectiveness in disease models and clinical trials, as well as elevated costs. In the recent years, a renewed interest has emerged on targeting innate immune cells for immunotherapy, due to their high plasticity and ability to exert a potent and extremely rapid response, which can influence the outcome of the adaptive immune response. In this review, we discuss the immunomodulatory potential of several innate immune cells, as well as they use for immunotherapy, especially in autoimmunity and cancer.

AB - Modulation of the immune system has been widely targeted for the treatment of several immune-related diseases, such as autoimmune disorders and cancer, due to its crucial role in these pathologies. Current available therapies focus mainly on symptomatic treatment and are often associated with undesirable secondary effects. For several years, remission of disease and subsequently recovery of immune homeostasis has been a major goal for immunotherapy. Most current immunotherapeutic strategies are aimed to inhibit or potentiate directly the adaptive immune response by modulating antibody production and B cell memory, as well as the effector potential and memory of T cells. Although these immunomodulatory approaches have shown some success in the clinic with promising therapeutic potential, they have some limitations related to their effectiveness in disease models and clinical trials, as well as elevated costs. In the recent years, a renewed interest has emerged on targeting innate immune cells for immunotherapy, due to their high plasticity and ability to exert a potent and extremely rapid response, which can influence the outcome of the adaptive immune response. In this review, we discuss the immunomodulatory potential of several innate immune cells, as well as they use for immunotherapy, especially in autoimmunity and cancer.

KW - autoimmunity

KW - cancer

KW - dendritic cells

KW - Innate immunity

KW - NKT cells

UR - http://www.scopus.com/inward/record.url?scp=85034590728&partnerID=8YFLogxK

U2 - 10.1080/08830185.2017.1365145

DO - 10.1080/08830185.2017.1365145

M3 - Review article

AN - SCOPUS:85034590728

VL - 36

SP - 315

EP - 337

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 6

ER -

Schäfer C, Ascui G, Ribeiro CH, López M, Prados-Rosales R, González PA et al. Innate immune cells for immunotherapy of autoimmune and cancer disorders. International Reviews of Immunology. 2017 Nov 2;36(6):315-337. https://doi.org/10.1080/08830185.2017.1365145